HealthcareServices

Revenue of the HER2-Negative Breast Cancer Market Predicted to Achieve $25.4 Billion by 2030, Driven by 7.6% CAGR

February 25, 2026February 25, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the her2-negative breast cancer market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the HER2-Negative Breast Cancer Market by the end of 2030?

The her2-negative breast cancer market size has shown robust growth in recent years. It is projected to expand from $17.57 billion in 2025 to $18.95 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.9%. The historical increase can be attributed to factors such as rising breast cancer screening rates, increased awareness of hormone receptor-positive cancers, the expansion of oncology treatment centers, the availability of established chemotherapy protocols, and growth in clinical oncology research.

The market for her2-negative breast cancer is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $25.41 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This projected expansion throughout the forecast period stems from factors such as a heightened demand for tailored oncology treatments, the increasing acceptance of genomic-based therapies, the widening scope of immunotherapy development, an enhanced emphasis on extending progression-free survival, and a greater influx of investment into developing oncology drugs. Key trends predicted for this period encompass the increased uptake of individualized hormone therapy approaches, the expanding application of cdk4/6 inhibitors, the broader utilization of genomic testing to guide treatment choices, the progressive incorporation of immunotherapy in advanced disease stages, and a sharpened focus on multi-modal treatment strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

What Drivers Are Shaping Future Opportunities In The HER2-Negative Breast Cancer Market?

The increasing occurrence of breast cancer cases is anticipated to drive the expansion of the HER2-negative breast cancer market in the future. Breast cancer is a condition marked by the unchecked proliferation of abnormal cells within breast tissue, typically starting in the ducts or lobules. The growing frequency of breast cancer cases stems from various factors, such as enhanced public awareness and better screening techniques, which facilitate earlier and more regular diagnosis. HER2-Negative Breast Cancer is vital for advancing research, offering clarity on unique tumor biology and therapeutic approaches, thus aiding in the creation of more targeted treatments. For example, the American Cancer Society, a US-based professional organization, forecasts that in 2025, the United States will experience around 316,950 new instances of invasive breast cancer in women and 2,800 cases in men, alongside an estimated 59,080 diagnoses of ductal carcinoma in situ (DCIS) in women. Consequently, the rising number of breast cancer cases is fueling the growth of the HER2-negative breast cancer market.

Which Segments Are Gaining Traction In The HER2-Negative Breast Cancer Market?

The her2-negative breast cancer market covered in this report is segmented –

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

What Trends Are Driving The Growth Trajectory Of The HER2-Negative Breast Cancer Market?

Major companies operating in the HER2-negative breast cancer market are actively seeking regulatory approvals to launch new treatments, expand their product offerings, and strengthen their market presence. Regulatory approvals signify the official authorization granted by government bodies, permitting companies to market and distribute drugs or therapies after fulfilling safety, efficacy, and quality requirements. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, secured FDA approval for Itovebi (inavolisib) as a targeted therapy for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval enables Itovebi to be utilized alongside palbociclib and fulvestrant, substantially enhancing progression-free survival for patients compared to existing standard treatments. This novel regimen provides an important choice for patients with limited therapeutic alternatives, highlighting the significance of biomarker testing to identify those who stand to gain the most from this treatment.

Who Are The Core Companies Influencing Trends In The HER2-Negative Breast Cancer Market?

Major companies operating in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The HER2-Negative Breast Cancer Market?

North America was the largest region in the HER2-negative breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-negative breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized HER2-Negative Breast Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp

Browse Through More Reports Similar to the Global HER2-Negative Breast Cancer Market 2026, By The Business Research Company

Breast Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Hr Her2 Breast Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-hr-her2-breast-cancer-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795